BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 31814045)

  • 1. The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF).
    Donnellan S; Wright DFB; Roberts JA; Duffull SB; Schollum JBW; Putt TL; Wallis SC; Walker RJ
    Eur J Clin Pharmacol; 2020 Feb; 76(2):239-247. PubMed ID: 31814045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
    Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study.
    Areskog Lejbman I; Torisson G; Resman F; Sjövall F
    Acta Anaesthesiol Scand; 2024 Apr; 68(4):530-537. PubMed ID: 38407447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration.
    Sinnollareddy MG; Roberts MS; Lipman J; Peake SL; Roberts JA
    J Antimicrob Chemother; 2018 Jun; 73(6):1647-1650. PubMed ID: 29506150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
    Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
    Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
    Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
    J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 10. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
    J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
    Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of common antimicrobial agents by sustained low-efficiency dialysis.
    Hudson JQ; Hilgers MN; Gosmanova EO
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0157923. PubMed ID: 38349160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.
    Olbrisch K; Kisch T; Thern J; Kramme E; Rupp J; Graf T; Wicha SG; Mailänder P; Raasch W
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):229-241. PubMed ID: 30368548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
    Thorsted A; Kristoffersson AN; Maarbjerg SF; Schrøder H; Wang M; Brock B; Nielsen EI; Friberg LE
    J Antimicrob Chemother; 2019 Oct; 74(10):2984-2993. PubMed ID: 31273375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.
    Kim YK; Kim HS; Park S; Kim HI; Lee SH; Lee DH
    J Antimicrob Chemother; 2022 Apr; 77(5):1353-1364. PubMed ID: 35224630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
    Chua NG; Loo L; Hee DKH; Lim TP; Ng TM; Hoo GSR; Soong JL; Ong JCL; Tang SSL; Zhou YP; Lee W; Lee LS; Cove M; Ling LM; Kwa AL
    J Crit Care; 2022 Apr; 68():107-113. PubMed ID: 34999376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.